• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

组蛋白去乙酰化酶驱动的抗癌耐药机制：表观遗传学及其他。

HDAC-driven mechanisms in anticancer resistance: epigenetics and beyond.

作者信息

Minisini Martina, Mascaro Martina, Brancolini Claudio

机构信息

Laboratory of Epigenomics, Department of Medicine, Università degli Studi di Udine, Udine 33100, Italy.

出版信息

Cancer Drug Resist. 2024 Nov 20;7:46. doi: 10.20517/cdr.2024.103. eCollection 2024.

DOI:10.20517/cdr.2024.103
PMID:39624079
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11609180/
Abstract

The emergence of drug resistance leading to cancer recurrence is one of the challenges in the treatment of cancer patients. Several mechanisms can lead to drug resistance, including epigenetic changes. Histone deacetylases (HDACs) play a key role in chromatin regulation through epigenetic mechanisms and are also involved in drug resistance. The control of histone acetylation and the accessibility of regulatory DNA sequences such as promoters, enhancers, and super-enhancers are known mechanisms by which HDACs influence gene expression. Other targets of HDACs that are not histones can also contribute to resistance. This review describes the contribution of HDACs to the mechanisms that, in some cases, may determine resistance to chemotherapy or other cancer treatments.

摘要

导致癌症复发的耐药性的出现是癌症患者治疗中的挑战之一。多种机制可导致耐药性，包括表观遗传变化。组蛋白去乙酰化酶（HDACs）通过表观遗传机制在染色质调控中发挥关键作用，并且也参与耐药性。组蛋白乙酰化的控制以及诸如启动子、增强子和超级增强子等调控DNA序列的可及性是HDACs影响基因表达的已知机制。HDACs的非组蛋白其他靶点也可能导致耐药性。本综述描述了HDACs在某些情况下可能决定对化疗或其他癌症治疗耐药性的机制中的作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2192/11609180/55c7c027a880/cdr-7-46.fig.3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2192/11609180/1f7ed8421755/cdr-7-46.fig.1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2192/11609180/625bbb43351d/cdr-7-46.fig.2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2192/11609180/55c7c027a880/cdr-7-46.fig.3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2192/11609180/1f7ed8421755/cdr-7-46.fig.1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2192/11609180/625bbb43351d/cdr-7-46.fig.2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2192/11609180/55c7c027a880/cdr-7-46.fig.3.jpg

相似文献

1
HDAC-driven mechanisms in anticancer resistance: epigenetics and beyond.组蛋白去乙酰化酶驱动的抗癌耐药机制：表观遗传学及其他。
Cancer Drug Resist. 2024 Nov 20;7:46. doi: 10.20517/cdr.2024.103. eCollection 2024.
2
Histone deacetylases modulate resistance to the therapy in lung cancer.组蛋白脱乙酰酶调节肺癌对治疗的耐药性。
Front Genet. 2022 Oct 3;13:960263. doi: 10.3389/fgene.2022.960263. eCollection 2022.
3
Histone deacetylases as targets in autoimmune and autoinflammatory diseases.组蛋白去乙酰化酶作为自身免疫和自身炎症性疾病的靶点。
Adv Immunol. 2020;147:1-59. doi: 10.1016/bs.ai.2020.06.001. Epub 2020 Jul 15.
4
Patho-epigenetics: histone deacetylases as targets of pathogens and therapeutics.病理表观遗传学：组蛋白去乙酰化酶作为病原体和治疗的靶点
Microlife. 2021 Nov 29;2:uqab013. doi: 10.1093/femsml/uqab013. eCollection 2021.
5
Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy.组蛋白去乙酰化酶及其抑制剂在抗癌治疗中的作用
Cancers (Basel). 2020 Jun 23;12(6):1664. doi: 10.3390/cancers12061664.
6
Histone tail modifications and noncanonical functions of histones: perspectives in cancer epigenetics.组蛋白尾部修饰与组蛋白的非经典功能：癌症表观遗传学视角
Mol Cancer Ther. 2008 Apr;7(4):740-8. doi: 10.1158/1535-7163.MCT-07-2284.
7
Multiple mechanisms regulate H3 acetylation of enhancers in response to thyroid hormone.多种机制调节增强子的 H3 乙酰化以响应甲状腺激素。
PLoS Genet. 2020 May 26;16(5):e1008770. doi: 10.1371/journal.pgen.1008770. eCollection 2020 May.
8
The emerging roles of HDACs and their therapeutic implications in cancer.组蛋白去乙酰化酶（HDACs）的新兴作用及其在癌症治疗中的意义。
Eur J Pharmacol. 2022 Sep 15;931:175216. doi: 10.1016/j.ejphar.2022.175216. Epub 2022 Aug 18.
9
The role dietary of bioactive compounds on the regulation of histone acetylases and deacetylases: a review.生物活性化合物的饮食对组蛋白乙酰转移酶和去乙酰化酶调节作用的综述
Gene. 2015 May 10;562(1):8-15. doi: 10.1016/j.gene.2015.02.045. Epub 2015 Feb 19.
10
Role of Histone Deacetylases (HDACs) in Epilepsy and Epileptogenesis.组蛋白去乙酰化酶（HDACs）在癫痫和癫痫发生中的作用。
Curr Pharm Des. 2017;23(37):5546-5562. doi: 10.2174/1381612823666171024130001.

引用本文的文献

1
Class IIa HDACs Are Important Signal Transducers with Unclear Enzymatic Activities.IIa类组蛋白去乙酰化酶是具有不明酶活性的重要信号转导分子。
Biomolecules. 2025 Jul 22;15(8):1061. doi: 10.3390/biom15081061.
2
Cellular Epigenetic Targets and Epidrugs in Breast Cancer Therapy: Mechanisms, Challenges, and Future Perspectives.乳腺癌治疗中的细胞表观遗传靶点与表观遗传药物：作用机制、挑战及未来展望
Pharmaceuticals (Basel). 2025 Feb 3;18(2):207. doi: 10.3390/ph18020207.
3
Epigenetic Regulation of Stromal and Immune Cells and Therapeutic Targets in the Tumor Microenvironment.

本文引用的文献

1
Development of a First-in-Class DNMT1/HDAC Inhibitor with Improved Therapeutic Potential and Potentiated Antitumor Immunity.开发具有改善的治疗潜力和增强的抗肿瘤免疫的首创类 DNMT1/HDAC 抑制剂。
J Med Chem. 2024 Sep 26;67(18):16480-16504. doi: 10.1021/acs.jmedchem.4c01310. Epub 2024 Sep 12.
2
PARPi, BRCA, and gaps: controversies and future research.聚腺苷二磷酸核糖聚合酶抑制剂（PARPi）、BRCA 基因和空白：争议与未来研究。
Trends Cancer. 2024 Sep;10(9):857-869. doi: 10.1016/j.trecan.2024.06.008.
3
Acetylation-dependent regulation of core spliceosome modulates hepatocellular carcinoma cassette exons and sensitivity to PARP inhibitors.
肿瘤微环境中基质细胞和免疫细胞的表观遗传调控及治疗靶点
Biomolecules. 2025 Jan 6;15(1):71. doi: 10.3390/biom15010071.
乙酰化依赖的核心剪接体调控可调节肝细胞癌的选择性外显子和对 PARP 抑制剂的敏感性。
Nat Commun. 2024 Jun 18;15(1):5209. doi: 10.1038/s41467-024-49573-7.
4
HDAC4 influences the DNA damage response and counteracts senescence by assembling with HDAC1/HDAC2 to control H2BK120 acetylation and homology-directed repair.组蛋白去乙酰化酶 4（HDAC4）通过与组蛋白去乙酰化酶 1/2（HDAC1/HDAC2）组装来控制 H2BK120 乙酰化和同源定向修复，从而影响 DNA 损伤反应并拮抗衰老。
Nucleic Acids Res. 2024 Aug 12;52(14):8218-8240. doi: 10.1093/nar/gkae501.
5
Advances in targeting histone deacetylase for treatment of solid tumors.靶向组蛋白去乙酰化酶治疗实体瘤的研究进展。
J Hematol Oncol. 2024 May 31;17(1):37. doi: 10.1186/s13045-024-01551-8.
6
CDK4/6 inhibitors: The Devil is in the Detail.CDK4/6 抑制剂：细节决定成败。
Curr Oncol Rep. 2024 Jun;26(6):665-678. doi: 10.1007/s11912-024-01540-7. Epub 2024 May 7.
7
Dynamic genomic changes in methotrexate-resistant human cancer cell lines beyond DHFR amplification suggest potential new targets for preventing drug resistance.甲氨蝶呤耐药的人类癌细胞系中除了二氢叶酸还原酶扩增之外的动态基因组变化提示了预防耐药性的潜在新靶点。
Br J Cancer. 2024 May;130(11):1819-1827. doi: 10.1038/s41416-024-02664-0. Epub 2024 Apr 9.
8
Pharmacological modulation of RB1 activity mitigates resistance to neoadjuvant chemotherapy in locally advanced rectal cancer.RB1 活性的药物调节可减轻局部晚期直肠癌对新辅助化疗的耐药性。
Proc Natl Acad Sci U S A. 2024 Feb 6;121(6):e2304619121. doi: 10.1073/pnas.2304619121. Epub 2024 Jan 30.
9
Structural insights into the HDAC4-MEF2A-DNA complex and its implication in long-range transcriptional regulation.结构洞察 HDAC4-MEF2A-DNA 复合物及其对长程转录调控的影响。
Nucleic Acids Res. 2024 Mar 21;52(5):2711-2723. doi: 10.1093/nar/gkae036.
10
Acetylation and Phosphorylation in the Regulation of Hypoxia-Inducible Factor Activities: Additional Options to Modulate Adaptations to Changes in Oxygen Levels.缺氧诱导因子活性调控中的乙酰化和磷酸化：调节对氧水平变化适应的其他选择。
Life (Basel). 2023 Dec 21;14(1):20. doi: 10.3390/life14010020.